This trial is active, not recruiting.

Condition low back pain
Treatments interspinous process and dynamic stabilization (wallis system), total disc replacement
Phase phase 3
Sponsor Zimmer Spine
Collaborator Zimmer, Inc.
Start date January 2007
End date November 2013
Trial size 340 participants
Trial identifier NCT00484458, 6000-1006-P1-R1


The purpose of this study is to demonstrate that the Wallis System (interspinous process implant) is equivalent to total disc replacement (TDR) for the treatment of mild to moderate degenerative disc disease (DDD) of the lumbar spine at the L4-L5 level.

This study will assess the safety and efficacy of the Wallis® System compared to commercially available lumbar TDR with respect to individual subject success rates at 24 months postoperative follow-up.

Study participants will receive all study related test articles and surgical procedures at no charge. Please scroll down to the "Locations" section to find a doctor in your area that is participating in this study. If you are interested in participating in this study and do not see a doctor in your area, please contact Jose Naveira at jose.naveira@abbottspine.com

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Wallis Stabilization System
interspinous process and dynamic stabilization (wallis system)
Interspinous stabilization
(Active Comparator)
Total Disc Replacement
total disc replacement
Total disc

Primary Outcomes

Non-inferior to commercially available lumber TDR after 24 months.
time frame: 24 months

Eligibility Criteria

Male or female participants from 18 years up to 60 years old.

Inclusion Criteria: - Age 18-60 (inclusive) and skeletally mature. - Diagnosis of mild to moderate DDD at L4-L5 as confirmed by radiography. - Minimum of six months of failed conservative treatment. - Pre-operative visual analog (VAS) low back pain score ≥ 40, on a scale of 100mm, with low back pain greater than left or right leg pain. - Preoperative baseline Oswestry Disability Index (ODI) score of ≥ 40 on a 100 point scale. - Physically and mentally able to comply with the protocol, including ability to read and complete required forms, and willing and able to adhere to the follow-up requirements of the protocol. - Voluntarily signs the patient informed consent form. - Patient is a surgical candidate for an anterior approach to the lumbar spine (< 3 abdominal surgeries). Exclusion Criteria: - The investigator believes that the L1-L2, L2-L3, L3-L4, or L5-S1 level is symptomatic based upon objective evidence, e.g., radiograph, MRI, or discography. - Evidence of a prior fracture or trauma to the vertebral bodies at the affected level and/or the spinous processes at the L4-L5 or adjacent levels. - Osteoporosis or osteopenia or metabolic bone disease as confirmed by DEXA scan (T score < -1.0). Female subjects older than 45 years of age (or post-menopausal women, history of oophorectomy, or family history of osteoporosis) and male subjects older than 55 years will undergo a pre-operative, dual energy x-ray absorptiometry (DEXA) of the lumbar spine. The DEXA will be used to identify subjects with an indication of osteoporosis, osteopenia or metabolic bone disease. Subjects with a T-score of less than -1.0 will be excluded from the study. - Congenital lumbar spinal stenosis. - Bony lumbar stenosis. - Extreme obesity, as defined by National Institutes of Health (NIH) Clinical Guidelines Body Mass Index (BMI > 40kg/m2). - A history of any surgical procedure intended to remove or alter the disc (e.g. discectomy, intradiscal electrothermal therapy (IDET) or enzymes), decompress (laminectomy) or fuse, either the index or adjacent levels. - Prior participation in study of any investigational spinal implant or investigational spinal treatment.

Additional Information

Official title A Prospective, Multi-center, Randomized, Active-Controlled Study of the Wallis System for the Treatment of Mild to Moderate Degenerative Disc Disease of the Lumbar Spine
Principal investigator John J. Regan, MD
Trial information was received from ClinicalTrials.gov and was last updated in October 2011.
Information provided to ClinicalTrials.gov by Zimmer Spine.